Factor XII Autoantibodies As a Novel Marker for Thrombosis and Adverse Obstetric History in Patients with Systemic Lupus Erythematosus

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2006 Oct 6

PMID 17020907

Citations 6

Authors

Maria Laura Bertolaccini

Kirti Mepani

Giovanni Sanna

Graham R V Hughes

Munther A Khamashta

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the clinical significance of anti-factor XII (FXII) in a large cohort of patients with systemic lupus erythematosus (SLE).

Patients And Methods: This study comprised 127 patients with SLE. IgG and IgM anti-FXII were tested by an in-house ELISA. 123 healthy donors comprised the control group.

Results: 51 (40%) patients with SLE and 9 (7%) healthy controls were positive for anti-FXII. IgG and IgM anti-FXII were frequently found in patients with thrombosis (28% and 13%, respectively). Levels of IgG and IgM anti-FXII were higher in patients with thrombosis than in the control group (p<0.001 and p=0.005, respectively). Anti-FXII was more frequent in patients with arterial thrombosis (31% vs 4% for IgG and 14% vs 3% for IgM, respectively) and venous thrombosis than in controls (37% vs 4% for IgG). IgG anti-FXII were more frequent in patients with miscarriages and fetal death (35% and 40% vs 4% for IgM). The prevalence of IgM anti-FXII was not different between groups.

Conclusion: Anti-FXII are frequent in patients with SLE. Their presence is associated with thrombosis and adverse obstetric history, making these antibodies a novel marker for the antiphospholipid syndrome.

Citing Articles

[Pathophysiology, diagnosis, and therapy for the management of acquired clotting factor deficiency].

Yu D, Liu W, Zhang L Zhonghua Xue Ye Xue Za Zhi. 2024; 44(11):956-962.

PMID: 38185529 PMC: 10753255. DOI: 10.3760/cma.j.issn.0253-2727.2023.11.014.

An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation.

Ryan T, ONeill L Cells. 2023; 12(5).

PMID: 36899914 PMC: 10001161. DOI: 10.3390/cells12050778.

Pathophysiology of Antiphospholipid Syndrome.

Green D Thromb Haemost. 2021; 122(7):1085-1095.

PMID: 34794200 PMC: 9391091. DOI: 10.1055/a-1701-2809.

Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus.

Back J, Lood C, Bengtsson A, Nilsson Ekdahl K, Nilsson B Arthritis Res Ther. 2013; 15(6):R206.

PMID: 24299152 PMC: 3979000. DOI: 10.1186/ar4399.

Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus.

Mok C, Ho L, Yu K, To C Clin Rheumatol. 2010; 29(6):599-604.

PMID: 20101427 DOI: 10.1007/s10067-009-1364-z.

References

Jones D, Gallimore M, Mackie I, Harris S, Winter M . Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol. 2000; 110(3):721-6. DOI: 10.1046/j.1365-2141.2000.02251.x. View

Bertolaccini M, Atsumi T, Koike T, Hughes G, Khamashta M . Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost. 2005; 93(2):289-97. DOI: 10.1160/TH04-06-0382. View

Kitchens C . The contact system. Arch Pathol Lab Med. 2002; 126(11):1382-6. DOI: 10.5858/2002-126-1382-TCS. View

Jones D, Gallimore M, Winter M . Antibodies to factor XII: a possible predictive marker for recurrent foetal loss. Immunobiology. 2003; 207(1):43-6. DOI: 10.1078/0171-2985-00207. View

Tan E, Cohen A, Fries J, MASI A, McShane D, Rothfield N . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11):1271-7. DOI: 10.1002/art.1780251101. View

Hughes G . Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed). 1983; 287(6399):1088-9. PMC: 1549319. DOI: 10.1136/bmj.287.6399.1088. View

Harris E, Gharavi A, Patel S, Hughes G . Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol. 1987; 68(1):215-22. PMC: 1542695. View

Levi M, Hack C, de Boer J, Brandjes D, Buller H, Ten Cate J . Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest. 1991; 88(4):1155-60. PMC: 295573. DOI: 10.1172/JCI115416. View

Amengual O, Atsumi T, Khamashta M, Koike T, Hughes G . Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol. 1996; 35(12):1239-43. DOI: 10.1093/rheumatology/35.12.1239. View

10.

Gallimore M, Jones D, Winter M . Factor XII determinations in the presence and absence of phospholipid antibodies. Thromb Haemost. 1998; 79(1):87-90. View

11.

Bertolaccini M, Atsumi T, Khamashta M, Amengual O, Hughes G . Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol. 1998; 25(6):1104-8. View

12.

Jones D, Gallimore M, Harris S, Winter M . Antibodies to factor XII associated with lupus anticoagulant. Thromb Haemost. 1999; 81(3):387-90. View

13.

Wilson W, Gharavi A, Koike T, Lockshin M, Branch D, Piette J . International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999; 42(7):1309-11. DOI: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F. View

14.

Ratnoff O, COLOPY J . A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest. 1955; 34(4):602-13. PMC: 438666. DOI: 10.1172/JCI103109. View

15.

Jones D, Mackie I, Gallimore M, Winter M . Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome. Br J Haematol. 2001; 113(2):550-2. DOI: 10.1046/j.1365-2141.2001.02776.x. View